Lawsuits filed against Allergan and its subsidiary, Actavis have claimed that use of Androderm patch has resulted in severe medical injuries including:
- Heart attack
- Pulmonary embolism
- Blood clots
- Deep vein thrombosis
- Venous thromboembolism
Thousands of men who used Androderm patches and experienced serious injury, have filed lawsuits against Actavis and Allergan.
Androderm – FDA Warnings
In January of 2014, after two large studies linked testosterone replacement therapy to an increased risk of heart attack and other cardiovascular events, the Food and Drug Administration (FDA) issued a safety warning indicating that they were beginning an investigation regarding the risks. This announcement was followed in mid-2015 with a requirement that all testosterone replacement products including Androderm gel and Androderm patch add safety warnings about the risk of heart attack, stroke and other cardiovascular events.
Separately, in June of 2014, the FDA also required that manufacturers add safety information about an increased risk of clotting disorders such as deep vein thrombosis (DVT) and venous thromboembolism (VTE). The risk of heart attack, blood clotting, stroke and other life-threatening events may be as much as two to three times greater when testosterone replacement therapy is used and is particularly notable during the first six to nine months of treatment.
Manufacturers of Androderm and other testosterone products have been accused of failing to warn the public about the risks of testosterone replacement therapy and encouraging the use of the hormone to improve symptoms of “Low-T”. Low-T is not an approved indication or reason to use testosterone, but a marketing term.
Many men who took testosterone for symptoms of Low-T such as decreased sex drive, low energy, loss of muscle mass and foggy thinking, were experiencing normal symptoms of aging and not a medical disorder. A large percentage of men who used testosterone therapy have never had their hormone levels verified but were subject to increased risk of life-threatening side effects with no clear evidence for use.
Androderm Lawsuit Settlements
Actavis, the subsidiary of larger pharmaceutical company Allergan, announced in July of 2018 that they had reached a tentative settlement agreement to resolve around 500 Androderm lawsuits. The cases to be settled were part of a larger group of around 8,000 federal testosterone therapy lawsuits which had been consolidated into multidistrict litigation (MDL). The lawsuits had been filed against a number of manufacturers for improper marketing practices which promoted the products for “Low-T” and concealed the serious risks of testosterone replacement therapy.
Terms of the settlement offer have not been publicly disclosed and more lawsuits may be expected but men or loved ones of those who were harmed by Androderm should seek legal advice. A legal expert will be able to evaluate each case and determine whether a lawsuit may be advisable. Past lawsuits for similar injuries have resulted in compensation for medical costs, lost wages, pain and suffering or for wrongful death if the victim has died.